OTLK Outlook Therapeutics, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1649989 · Fiscal year ends 09/30
Financial factors as of 2026-06-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-40.7%
TTM EPS YoY16.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin195.6%
Operating margin4,781.8%
Net margin5,253.5%
FCF margin—
EBITDA margin4,772.9%
Returns
ROE—
ROA-251.7%
ROIC (approx.)—
Asset turnover-0.05x
Leverage & solvency
Liabilities / assets139.7%
Debt / equity—
Current ratio0.81x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.92x
Accruals ratio-20.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q3*2026-06-30 | 2026Q2*2026-03-31 | 2026Q1*2025-12-31 | 2025Q4*2025-09-30 | 2025Q32025-06-30 | 2025Q22025-03-31 | 2025Q12024-12-31 | 2024Q4*2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $8,700 | $127,439 | -$1.21M | -$91,787 | $1.51M | — | — | — |
| Cost of revenue | $16,965 | $149,327 | $29,626 | $916,515 | $439,815 | — | — | — |
| Gross profit | -$8,265 | -$21,888 | -$1.24M | -$1.01M | $1.07M | — | — | — |
| R&D expense | $3.25M | $4.50M | $3.63M | $5.98M | $7.13M | $4.41M | $9.66M | $12.52M |
| SG&A expense | $7.55M | $9.50M | $8.61M | $10.33M | $9.68M | $7.98M | $11.95M | $10.35M |
| Operating income | -$10.81M | -$14.03M | -$13.48M | -$17.31M | -$15.75M | -$12.39M | -$21.61M | -$22.88M |
| Interest expense | — | — | — | — | — | — | — | $0 |
| Pretax income | -$20.32M | -$4.45M | — | -$14.85M | -$20.15M | -$46.35M | — | $5.69M |
| Income tax | — | — | — | -$1.55M | $0 | $2,800 | — | $0 |
| Net income | -$20.32M | -$4.45M | -$23.06M | -$13.29M | -$20.15M | -$46.36M | $17.38M | $5.69M |
| EBITDA | -$10.80M | -$14.00M | -$13.45M | -$17.28M | -$15.72M | -$12.36M | -$21.58M | -$22.85M |
| EPS (basic) | -0.15 | -0.05 | -0.38 | — | -0.55 | -1.50 | 0.72 | — |
| EPS (diluted) | -0.15 | -0.05 | -0.38 | — | -0.55 | -1.50 | 0.72 | — |
| Weighted avg. shares (diluted) | 136.74M | 81.84M | 60.21M | — | 36.96M | 30.87M | 24.23M | — |
| Banking | ||||||||
| Net interest income | $7 | $3 | $0 | -$264,156 | -$49,351 | -$18,502 | $48,881 | -$666,199 |
| Balance sheet | ||||||||
| Cash & equivalents | $11.24M | $7.75M | $8.68M | $8.08M | $8.90M | $7.56M | $5.70M | $14.93M |
| Receivables | $1.64M | $2.72M | $114,609 | $1.49M | $1.75M | — | — | — |
| Inventory | $5.04M | $3.34M | $3.46M | $3.34M | $4.13M | $3.60M | $3.11M | — |
| Current assets | $23.17M | $20.90M | $17.17M | $17.39M | $21.10M | $17.81M | $15.67M | $27.42M |
| Total assets | $26.18M | $21.89M | $18.24M | $18.58M | $22.39M | $19.08M | $17.01M | $28.82M |
| Current liabilities | $28.68M | $38.88M | $49.06M | $45.81M | $31.49M | $24.82M | $48.24M | $42.55M |
| Total liabilities | $36.58M | $50.89M | $56.79M | $50.77M | $59.58M | $51.54M | $67.30M | $101.90M |
| Shareholders' equity | -$10.39M | -$28.99M | -$38.55M | -$32.19M | -$37.19M | -$32.46M | -$50.29M | -$73.08M |
| Shares outstanding | 187.10M | 104.61M | 64.56M | 53.89M | 43.48M | 32.91M | 24.91M | 23.91M |
| Cash flow statement | ||||||||
| Operating cash flow | -$21.01M | -$7.83M | -$14.94M | -$12.38M | -$11.90M | -$16.58M | -$10.97M | -$16.98M |
| Financing cash flow | $26.60M | $6.90M | $15.53M | $11.56M | $13.25M | $18.44M | $1.74M | -$114,954 |
| Depreciation & amortization | $13,791 | $30,417 | $30,074 | $29,737 | $29,412 | $29,102 | $28,801 | $28,797 |
| Stock-based compensation | $791,671 | $757,483 | $881,150 | $1.82M | $1.67M | $1.70M | $3.67M | $1.41M |
Free plan shows the latest 8 periods; Pro shows all 46 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.